Attovia Therapeutics (NASDAQ:ATTO) Director Colin Walsh Buys 500,000 Shares

Attovia Therapeutics, Inc. (NASDAQ:ATTO) Director Colin Walsh purchased 500,000 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the purchase, the director owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Colin Walsh also recently made the following trade(s):

• On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The stock was sold at an average price of $21.28, for a total value of $2,251,572.96.

Attovia Therapeutics Stock Performance

Shares of Attovia Therapeutics stock opened at $19.18 on Friday. Attovia Therapeutics, Inc. has a 12 month low of $16.15 and a 12 month high of $22.79.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. lifted its holdings in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.